Biogen and Japan’s Eisai Co. said early results showed that the treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo after 18 months of the infused treatment.
Every 60 seconds, someone in the U.S. is diagnosed with Alzheimer's Disease. Researchers are making big strides in learning more about Alzheimer's Disease. By understanding it, they're developing ways to diagnose it earlier -- that could mean prevention in some people. NBC10 Boston's Dustin Wlodkowski explains the breakthroughs in Alzheimer's research.
Alzheimer’s has no known cure. Long-standing treatments on the market just manage symptoms, and researchers don’t fully understand what causes the disease. Earlier this year, the federal Medicare program imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. Biogen announced afterward that it would stop most of its spending on the treatment.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Alzheimer's drug study yields positive results, say makers Eisai and BiogenAn experimental Alzheimer's drug made by Eisai Co. Ltd. and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
Les mer »
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNNA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Les mer »
Biogen stock increases as Alzheimer's drug shows promise in early results of studyEisai announced results from a global study of nearly 1,800 people with early-stage Alzheimer’s. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.
Les mer »
Alzheimer's drug shows promise in early results of studyJapan's Eisai Co. said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. abc15
Les mer »
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Les mer »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Les mer »